In vitro effect of hydroxyethyl starch 130/0.42 on canine platelet function

Abstract

Saline solution and HES 130/0.42 in a 1:3 dilution affected canine platelet function by prolonging Cts. The HES 130/0.42 had a significantly greater effect on canine platelets than did saline solution.

Platelet closure time in anesthetized Greyhounds with hemorrhagic shock treated with hydroxyethyl starch 130/0.4 or 0.9% sodium chloride infusions

“…No significant change in PCT beyond the effect of hemodilution in our study may be due to the low MW and MS of HES 130/0.4. In contrast, HES 130/0.42 diluted 1:3 with canine whole blood increased PCT beyond dilutional effect in vitro . However, the different properties of HES 130/0.42 make direct comparisons with HES 130/0.4 difficult.…”

“…effect in vitro. 21 However, the different properties of HES 130/0.42 make direct comparisons with HES 130/ 0.4 difficult. The failure to cause a significant change in PCT with HES 130/0.4, beyond hemodilution, may also be explained by the use of a 20 mL/kg dose.…”

“…There have been 2 recent in vitro studies using the PFA‐100 to assess the effect of low MW and low MS HES solutions on canine platelet function . One study using HES 130/0.42 found that it caused a mild prolongation in PCT, whereas one using HES 130/0.4 found no effect .…”

Effect of Synthetic Colloid Administration on Coagulation in Healthy Dogs and Dogs with Systemic Inflammation

“…In vitro and in vivo reports demonstrate that higher MW HES are associated with platelet dysfunction characterized by prolonged closure time using PFA‐100 31, 32. In vitro dilution with a lower MW product HES 130/0.42 also causes hypocoagulability manifested by prolonged closure time using PFA‐100 33. However, a recent study investigating the effect of tetrastarch on coagulation in a hemorrhagic shock model in dogs found no difference in platelet function as assessed with PFA‐100 34.…”

Acute kidney injury in severe sepsis: Pathophysiology, diagnosis, and treatment recommendations

“…Despite wide spread use of both crystalloids and colloids in veterinary critical care units there are very few studies assessing the clinical effects of these fluids on patient outcomes. There is a growing body of evidence demonstrating coagulation defects associated with the use of HES in both healthy and critical ill dogs . It has yet to be established if the use of HES in the management of sepsis in veterinary patients is of clinical benefit or if indeed causes harm.…”